Aquestive Therapeutics, Inc. (AQST) Analysts See $-0.79 EPS

Analysts expect Aquestive Therapeutics, Inc. (NASDAQ:AQST) to report $-0.79 EPS on November, 5.They anticipate $0.30 EPS change or 61.22 % from last quarter’s $-0.49 EPS. After having $-0.82 EPS previously, Aquestive Therapeutics, Inc.’s analysts see -3.66 % EPS growth. It closed at $3.16 lastly. It is down 77.36% since October 7, 2018 and is downtrending. It has underperformed by 77.36% the S&P500.

Aquestive Therapeutics, Inc., a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company has market cap of $80.14 million. The Company’s products are developed using its PharmFilm technology. It currently has negative earnings. The company's marketed products include Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron antagonist for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery.

More notable recent Aquestive Therapeutics, Inc. (NASDAQ:AQST) news were published by: which released: “Aquestive Therapeutics Completes $70 Million Debt Refinancing – PRNewswire” on July 15, 2019, also with their article: “Aquestive Therapeutics Appoints Gary H. Slatko, MD as Chief Medical Officer – PRNewswire” published on January 03, 2019, published: “Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q2 2019 Results – Earnings Call Transcript – Seeking Alpha” on August 07, 2019. More interesting news about Aquestive Therapeutics, Inc. (NASDAQ:AQST) were released by: and their article: “Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q1 2019 Results – Earnings Call Transcript – Seeking Alpha” published on May 11, 2019 as well as‘s news article titled: “Aquestive Therapeutics Launches SYMPAZANâ„¢ (clobazam) Oral Film with Widespread US Availability – PRNewswire” with publication date: November 29, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.